store at -20°C
Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compound exhibits high antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compound exhibits high antitumor activity. |
In vitro | Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) specifically binds to TROP2, leading to its internalization into tumor cells, where it undergoes intracellular trafficking to the lysosome, resulting in the release of Deruxtecan. This process triggers DNA damage and induces apoptosis in TROP2-expressing tumor cells in vitro[1]. |
In vivo | Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) exhibits robust antitumor effects, achieving tumor regression in various TROP2-expressing xenograft models, such as those derived from non-small cell lung cancer (NSCLC) patients. Additionally, safety assessments in rats and cynomolgus monkeys indicate that Datopotamab deruxtecan has an acceptable safety profile[1]. |
Synonyms | Dato-DXd, DS-1062 |
Molecular Weight | N/A |
CAS No. | 2238831-60-0 |
store at -20°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Datopotamab deruxtecan 2238831-60-0 Others DS 1062 Dato-DXd DS-1062 DS1062 inhibitor inhibit